Rick E. Winningham - 25 Feb 2022 Form 4 Insider Report for Theravance Biopharma, Inc. (TBPH)

Role: CHIEF EXECUTIVE OFFICER, Director
Signature: /s/ Brett A. Grimaud, Attorney-in-Fact
Issuer symbol: TBPH
Transactions as of: 25 Feb 2022
Net transactions value: $0
Form type: 4
Filing time: 01 Mar 2022, 18:18:23 UTC
Previous filing: 23 Feb 2022
Next filing: 24 May 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	TBPH	Ordinary Shares	Award	$0	+170,000	+13%	$0.000000	1,449,300	25 Feb 2022	Direct
holding	TBPH	Ordinary Shares						92,567	25 Feb 2022	By Trust

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	TBPH	Share Option (Right to Buy)	Award	$0	+515,000		$0.000000	515,000	25 Feb 2022	Ordinary Shares	515,000	$10.24	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	25% of this option may be exercised when the optionee completes 12 months of continuous Service after the Date of Grant. Any remaining unvested shares may be exercised with respect to an additional 1/48th of the shares subject to the option when the optionee completes each month of continuous Service thereafter.